Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough

Treatment for the Most Common Form of Heart Disease

ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronary Stent System. Based on the product's innovative design and strong clinical data, the next-generation drug eluting stent represents a significant advance in the treatment of coronary artery disease.

Abbott's XIENCE V stent was approved by the United States Food and Drug Administration (FDA) and launched in July 2008, providing a new treatment option for the nearly 13 million Americans with coronary artery disease, the leading cause of death for both men and women in the United States. Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart. A drug eluting stent releases a medication (everolimus, in the case of XIENCE V) in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is the only drug eluting stent to demonstrate superiority over the previous market-leading drug eluting stent in two randomized, pivotal clinical trials -- and XIENCE V has become the market-leading drug eluting stent in just three months since launch.

This is the fourth Chicago Innovation Award that Abbott has received in six years. Most recently, the company's m2000(TM) molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test received the honor in 2007. In 2005, the company's PathVysion(TM) breast cancer test received the honor, and in 2003, HUMIRA(TM), the first human monoclonal antibody drug for rheumatoid arthritis, won the award.

"At Abbott, we are proud to be in the business of developing innovative treatments that improve and save lives," said Miles D. White, chairman and chief executive officer, Abbott. "Receivi
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... September 18, 2014 Texas Governor ... Sharp, Texas A&M Health Science Center CEO Brett ... of Health and Human Services (HHS), State of ... national pandemic influenza vaccine manufacturing facility in Bryan, ... anchor for the Texas A&M Biocorridor – a ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) ... to their offering. The global companion ... of 22.7% from 2014 to 2019. Factors such as ... adoption of companion diagnostics by the pharmaceutical industry, support ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Biotechnology companies are building on what they ... decade and are expected to drive this market ... Genetic Engineering and Biotechnology News ( GEN ... number of advantages, including reducing reagent consumption, increasing ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions company ... to the agricultural and consumer,market, announced today that it ... an Investor. , Mach One ... for,its first production facility in Wisconsin. The Original ...
... ABAX ), a medical products company manufacturing point-of-care ... its financial results for the third quarter of fiscal year ... 4:15 p.m. ET on Thursday, January 29, 2009.Participants can dial ... or can listen via a live Internet web cast, which ...
Cached Biology Technology:GEN Reports on Growing Reliance on Microfluidics Technology 2Mach One Completes Note Exchange 2Abaxis to Report Third Quarter Fiscal 2009 Financial Results Thursday, January 29, 2009 2
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... information is stored in DNA, tiny strands of nucleic ... bodies. To express this genetic data, our DNA is ... into proteins that perform tasks in our cells. ... of RNA molecule. Unlike all other known RNAs, this ... circRNA molecules are abundant, little has been known about ...
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... heart-healthy, essential omega-3 fatty acid is about to improve ... advance will move biotechnology onto the average consumer,s daily ... deliver positive environmental impacts and increase production to feed ... on Horizon , Recently, the U.S. Food and Drug ...
... COLLEGE STATION "Four and 20 black birds baked in ... discovery, backed by DNA analysis, means scientists now know there is ... Africa than was previously thought. And if Dr. Gary Voelker has ... its susceptibility to the deforestation now occurring across its native habitat. ...
... two different protection programs to safeguard them from getting ... stopping and developing cancer. Until now, researchers assumed that ... Now for the first time, using an animal model ... (MDC) Berlin-Buch and the Charit University Hospital Berlin ...
Cached Biology News:New biotech advance to add heart healthy omega-3s to US diet 2African bird discovery proves there is something new under the sun 22 at 1 stroke -- how cells protect themselves from cancer 2
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: